GLP-1s After Cancer: 10 Studies for a Population the Trials Excluded

The most directly relevant dataset published: a cancer-center cohort tracking weight-loss trajectories and outcomes in breast cancer survivors who started semaglutide or tirzepatide after finishing primary treatment, for weight gained from chemotherapy, aromatase inhibitors or tamoxifen. ★ Its central finding is that survivors did lose meaningful weight but on a different trajectory and scale than the registration trials report — which is exactly why extrapolating trial numbers to this population was never safe. Observational, with no placebo group.

PMID 41677473 ↗DOI 10.1158/2767-9764.CRC-25-0554 ↗

The first cardiovascular outcomes analysis dedicated to women carrying both breast cancer and type 2 diabetes, comparing those who started a GLP-1 against those started on other diabetes drugs in a large claims dataset. Fewer cardiovascular events on the GLP-1, consistent with what the big trials show in the general population. ⚠ Confounding by indication is the live problem here, and cancer stage — which drives both prognosis and prescribing — was incompletely captured. A bridge to a trial, not a substitute for one.

PMID 41801847 ↗DOI 10.1002/phar.70130 ↗

An examination of who actually receives weight-management treatment after breast cancer — drugs, surgery or behavioral programs — and what happens to their cardiovascular risk afterward. ⚠ Its limitation is a matter of timing: prescription data ends in 2023, before access to these drugs widened sharply, so the treatment mix it describes is already historical. It is most useful for the disparity question, which is who gets offered anything at all.

PMID 40360855 ↗DOI 10.1007/s10549-025-07714-6 ↗

A registry study setting older women who had survived an obesity-related cancer against those who had not, drawn from a period when the modern drugs barely existed. ★ Read it as the baseline rather than as evidence about GLP-1s: it establishes that this population carries measurably elevated cardiovascular risk, and that weight-management medication reached very few of them and unevenly. That is the gap the current era is filling, and this is what it is being measured against.

PMID 42083112 ↗DOI 10.1002/oby.70211 ↗

The strongest population-level evidence here, and it tests no drug at all. Using national insurance data, it tracked how weight change after a breast cancer diagnosis relates to later cardiovascular disease, and found risk elevated at both ends — gaining weight and losing a lot of it — with stability in the middle. ⚠ That U-shape needs care in interpretation: unintended weight loss after cancer often signals disease rather than causing harm. It is the best available proxy for what controlled weight reduction might deliver, and it is a proxy.

PMID 39762706 ↗DOI 10.1007/s10549-024-07594-2 ↗

An editorial arguing that oncology has been slow to bring effective obesity treatment into cancer care across prevention, treatment and survivorship, and setting out the trials, guidelines and coverage barriers standing in the way. ★ No new data. It is the framing document oncology weight-management programs are writing local protocols from, which makes it more consequential in practice than several of the cohorts above.

PMID 41954902 ↗DOI 10.1001/jamaoncol.2026.0260 ↗

A survivorship-curriculum chapter integrating lifestyle, weight management and psychological care after breast cancer, and one of the first mainstream oncology-education sources to name these drugs as a survivorship tool rather than strictly an obesity-medicine one. ⚠ Educational positioning is not a guideline endorsement, and it stops deliberately short of one. If a survivor asks whether their oncology society backs this use, this is the accurate answer to give them.

PMID 42127339 ↗DOI 10.1200/EDBK-26-517396 ↗

The only review focused on tamoxifen-associated weight gain specifically — a problem affecting a large share of premenopausal survivors across five to ten years of therapy, and one rarely addressed on its own. It covers lifestyle and drug options, and how the moment you intervene interacts with endocrine therapy still in progress. ★ Its most valuable feature is candor: it states outright that no randomized data exists in this exact population, and offers a practical approach anyway.

PMID 42170166 ↗DOI 10.6004/jadpro.2026.17.3.3 ↗

A systematic review of diet, nutrition and hormone therapy in prostate cancer, and the closest published synthesis of the androgen-deprivation weight problem. That therapy reliably drives visceral fat gain, muscle loss, insulin resistance and elevated cardiovascular mortality — a combination that plausibly responds differently to these drugs than ordinary obesity does. ★ The authors map what has been tried, note that no dedicated randomized trial exists in men on this therapy, and call for one. That call is the paper's contribution.

PMID 41703670 ↗DOI 10.1093/jncics/pkag014 ↗

A single case report, included as illustration rather than evidence: a man who developed severe visceral obesity, fatty liver and new type 2 diabetes after surgical removal of the testes for prostate cancer. ⛔ One patient, no GLP-1 treatment involved. It earns its place by compressing into one case the metabolic trajectory that androgen deprivation produces gradually over years, which is the reason this whole question is being asked.

PMID 32522924 ↗DOI 10.2169/internalmedicine.4653-20 ↗